Pharmacodynamic analysis of BCR signaling using phospho-BTK protein as a biomarker clearly demonstrated that in circulating CLL cells of the 16 patients evaluated, this pathway was hampered during the four cycles of ibrutinib monotherapy. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.